octreotide sustained release (MTD201) / Biodexa Pharma - LARVOL DELTA

Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy. (PubMed, Expert Opin Investig Drugs) - "The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently under investigation as paltusotine, ONO-5788, AP102, GT-02037, ISIS 766,720, CAM2024, Lanreotide PRF, DP1038, MTD201, solid dose injection of octreotide. Current studies are addressing patient's needing for both new molecules and less invasive routes of administration for already existing drugs. It cannot be ruled out that drugs currently used for other disease such as cancers could be considered in the future for the treatment of acromegaly."

Journal • Review • Acromegaly • Endocrine Disorders • Oncology

Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase - Design, synthesis and biological evaluation. (PubMed, Comput Struct Biotechnol J) - "The complex and multifactorial nature of neuropsychiatric diseases demands multi-target drugs that can intervene with various sub-pathologies underlying disease progression. MTDL-201 was also devoid of hepatotoxicity in vivo. Given the therapeutic potential of MTDLs in disease-modifying therapy, our studies revealed several promising MTDLs among which 201 appears to be a potential candidate for immediate preclinical evaluations."

Journal • Alzheimer's Disease • CNS Disorders • Hepatology • Mental Retardation • Pain • Psychiatry • Vascular Neurology

Restructure underway at Midatech Pharma (Insider) - "'Rolf Stahel said: 'On behalf of the board, I would like to place on record our sincere thanks to Dr Craig Cook for his leadership, work and tireless efforts over many years establishing our leading edge technologies and pipeline in the most difficult of circumstances, and wish him every success in the future....He added: 'These are unprecedented times and the decisions we are announcing today regarding MTD201, our Bilbao manufacturing facility, and staff are regrettable but also necessary to give Midatech time to find and deliver a solution for all stakeholders."

Media quote

[VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO-I 2020) - "All subjects received Sandostatin® (100μg immediate release; SIR) by deep SC injection 24h before MTD201... MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume."

Clinical • Late-breaking abstract • PK/PD data • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • IGF1

Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO 2020) - "MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume."

Clinical • Late-breaking abstract • PK/PD data • IGF1

MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects (ENDO 2019) - "MTD201 uses Q-Sphera™ printing technology to precisely control microparticle size, which facilitates simpler reconstitution and injection using smaller needle size than Sandostatin LAR (SLAR) or Somatuline Autogel. MTD201 produced a safe and effective sustained-release profile of octreotide, supporting a once-monthly treatment interval, as is indicated for SLAR. Therapeutic octreotide concentrations and GH/IGF-1 suppression comparable with SLAR were achieved. Combined with the other advantages for MTD201 regarding smaller needle size, simpler and more reliable reconstitution and injection, these results warrant further study in a suitably powered clinical trial to formally establish MTD201 as an alternative long-acting somatostatin analogue product.*Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation."

Clinical

MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects (ENDO 2019) - "MTD201 uses Q-Sphera™ printing technology to precisely control microparticle size, which facilitates simpler reconstitution and injection using smaller needle size than Sandostatin LAR (SLAR) or Somatuline Autogel. MTD201 produced a safe and effective sustained-release profile of octreotide, supporting a once-monthly treatment interval, as is indicated for SLAR. Therapeutic octreotide concentrations and GH/IGF-1 suppression comparable with SLAR were achieved. Combined with the other advantages for MTD201 regarding smaller needle size, simpler and more reliable reconstitution and injection, these Results warrant further study in a suitably powered clinical trial to formally establish MTD201 as an alternative long-acting somatostatin analogue product."

Clinical

"Midatech Pharma $MTPH FDA feedback on clinical plan for MTD201 https://t.co/afuu52JvXv" (@BiotechRadar)

Clinical